Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Make a selection below to explore our full database of 6 results matching: "C Libanati"
ACE Reports
(6 Reports)
ACE Reports
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
General Orthopaedics
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Metabolic Disorders
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy
Metabolic Disorders
Differing effects of denosumab and alendronate on cortical and trabecular bone
Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.
Differing effects of denosumab and alendronate on cortical and trabecular bone
This report has been verified by one or more authors of the original publication.
Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.
Metabolic Disorders
Changes in lumbar spine QCT, DXA, and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass
Changes in lumbar spine QCT, DXA, and TBS following treatment with denosumab (DMAB), alendronate (ALN), or placebo (PBO) in postmenopausal women with low bone mass
Metabolic Disorders
Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing: Results from the FREEDOM Trial
J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing: Results from the FREEDOM Trial
This report has been verified by one or more authors of the original publication.
J Bone Joint Surg Am. 2012 Oct 24. doi: 10.2106/JBJS.K.00774
General Orthopaedics
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.